SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients

SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients

Abstract Background Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination reduces the risk and severity of coronavirus disease 2019 (COVID-19), several variables may impact the humoral response among patients undergoing hematopoietic stem cell transplantation (HSCT). Meth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infectious Diseases 2023-07, Vol.10 (7), p.ofad349-ofad349
Hauptverfasser: Kokogho, Afoke, Crowell, Trevor A, Aleissa, Muneerah, Lupan, Ana-Mihaela, Davey, Sonya, Park Chang, Jun Bai, Baden, Lindsey R, Walsh, Stephen R, Sherman, Amy C
Format: Artikel
Sprache:eng
Schlagworte:
Analysis
B cells
Coronaviruses
Electronic components industry
Health aspects
Hematopoietic stem cells
Immune response
Immunoglobulin G
Major
Pharmaceutical industry
Stem cells
Transplantation
Vaccination
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination reduces the risk and severity of coronavirus disease 2019 (COVID-19), several variables may impact the humoral response among patients undergoing hematopoietic stem cell transplantation (HSCT). Methods A retrospective chart review was conducted among SARS-CoV-2-vaccinated HSCT recipients between 2020 and 2022 at a single center in Boston, Massachusetts. Patients age ≥18 years who received doses of Pfizer, Moderna, or J&J vaccines were included. Anti-spike (S) immunoglobulin G (IgG) titer levels were measured using the Roche assay. Responders (≥0.8 U/mL) and nonresponders (
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofad349